Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Aroa Biosurgery Ltd

Healthcare AU ARX

0.525AUD
0.01(2.94%)

Last update at 2025-06-25T05:16:00Z

Day Range

0.510.54
LowHigh

52 Week Range

0.350.81
LowHigh

Fundamentals

  • Previous Close 0.51
  • Market Cap172.96M
  • Volume504573
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.26M
  • Revenue TTM84.70M
  • Revenue Per Share TTM0.25
  • Gross Profit TTM 72.61M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -0.35945M -7.67822M -17.53603M -6.16000M -3.04700M
Minority interest - - - - -
Net income -0.37068M -7.79440M -17.63426M -5.95800M 0.96M
Selling general administrative 47.71M 28.54M 19.98M 16.67M 11.86M
Selling and marketing expenses 44.66M 28.54M 19.98M - -
Gross profit 50.06M 28.17M 14.25M 18.74M 16.31M
Reconciled depreciation 3.59M 2.91M 2.83M - -
Ebit -0.35383M -6.98113M -16.15808M -2.84300M 0.88M
Ebitda 3.24M -4.07101M -13.33150M - -
Depreciation and amortization 3.59M 2.91M 2.83M - -
Non operating income net other - - - - -
Operating income -0.35383M -6.98113M -16.15808M -2.84300M 0.88M
Other operating expenses 67.44M 47.93M 34.96M 0.13M 0.19M
Interest expense 0.00562M 0.70M 1.38M 1.01M 0.00000M
Tax provision 0.01M 0.12M 0.10M -0.20200M -4.00700M
Interest income 2.73M 0.37M 0.14M 0.59M 1.27M
Net interest income 0.87M -0.69709M -1.75067M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01M 0.12M 0.10M -0.20200M -4.00700M
Total revenue 59.31M 36.88M 20.51M 25.08M 23.32M
Total operating expenses 58.19M 39.22M 28.70M - 5.73M
Cost of revenue 9.25M 8.72M 6.26M 6.34M 7.00M
Total other income expense net 3.30M 1.16M -4.30460M - -0.16657M
Discontinued operations - - - - -
Net income from continuing ops -0.37068M -7.79440M -17.63426M - -5.89237M
Net income applicable to common shares -0.39600M -8.38600M -19.20900M -5.95800M 0.96M
Preferred stock and other adjustments - - - - -
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 101.82M 109.07M 104.71M 73.12M 82.54M
Intangible assets - 11.31M 10.90M 11.51M 18.58M
Earning assets - - - - -
Other current assets 1.66M 10.36M 1.23M 18.36M 1.60M
Total liab 14.78M 13.69M 11.30M 19.43M 19.68M
Total stockholder equity 87.04M 95.38M 93.40M 53.69M 62.86M
Deferred long term liab - 1.33M - - -
Other current liab 6.24M 5.10M 4.45M 3.70M 1.30M
Common stock 134.59M 137.13M 135.47M 89.34M 94.30M
Capital stock - 137.13M 135.47M 89.34M 94.30M
Retained earnings -56.98378M -48.22990M -47.52115M -39.23804M -32.65575M
Other liab - - 0.16M 0.16M 0.16M
Good will 5.08M 5.18M 5.15M 5.08M 5.54M
Other assets - 0.13M 0.15M 0.17M 0.19M
Cash 10.56M 8.93M 5.73M 14.12M 41.48M
Cash and equivalents - - - - -
Total current liabilities 8.72M 7.41M 6.24M 14.04M 6.13M
Current deferred revenue 0.00000M - - - -
Net debt -3.74715M -2.27745M -0.26861M 0.78M -27.05372M
Short term debt 0.92M 0.52M 0.55M 9.66M 1.03M
Short long term debt - - - 9.14M 0.82M
Short long term debt total 6.82M 6.65M 5.46M 14.90M 14.42M
Other stockholder equity 0.00000M 0.00000M 5.86M 3.91M 1.79M
Property plant equipment - 20.64M 15.36M 12.66M 8.73M
Total current assets 63.29M 73.14M 74.24M 44.75M 55.25M
Long term investments - - - - -
Net tangible assets - 85.60M 83.22M 40.41M -11.45100M
Short term investments 17.15M 34.07M 47.62M 19.81M 0.94M
Net receivables 26.49M 13.41M 15.96M 6.60M 7.33M
Long term debt - - - 0.00000M 1.12M
Inventory 7.43M 4.52M 3.70M 3.31M 3.90M
Accounts payable 1.57M 1.79M 1.24M 0.68M 3.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 9.44M 6.48M 5.45M 3.59M 1.22M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 13.08M 0.12M 0.14M 0.16M 0.19M
Deferred long term asset charges - - - - -
Non current assets total 38.53M 35.93M 30.46M 28.37M 27.28M
Capital lease obligations - 6.65M 5.46M 5.77M 2.03M
Long term debt total - 6.55M 5.29M 5.72M 2.99M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments 6.79M -30.00000M -20.00000M -20.00000M -20.00000M
Change to liabilities - 1.32M -0.29800M 2.27M 0.73M
Total cashflows from investing activities 7.25M -34.87100M -21.50000M -1.87000M -3.70500M
Net borrowings - -10.08900M -12.91800M -6.10200M -4.73000M
Total cash from financing activities -0.47178M 34.98M 34.06M -0.38400M 4.13M
Change to operating activities - -1.33700M -0.82600M -0.02600M -0.08300M
Net income -0.37068M -8.38600M -19.20900M -5.95800M 0.96M
Change in cash 3.16M -8.56585M 10.59M -0.60700M 0.58M
Begin period cash flow 5.77M 14.30M 3.53M - -
End period cash flow 8.93M 5.73M 14.12M 3.53M -
Total cash from operating activities -3.77200M -11.52200M -5.00700M 1.66M -0.00700M
Issuance of capital stock 0.49M 46.77M 32.09M - -
Depreciation - 3.13M 3.05M 2.72M 2.06M
Other cashflows from investing activities 14.87M -30.00000M -20.00000M -20.00000M -20.00000M
Dividends paid - - 18.18M - -
Change to inventory - -0.32300M 0.63M -1.32700M -0.88900M
Change to account receivables - -10.38800M -0.48900M -1.67500M -2.66100M
Sale purchase of stock -0.95853M -2.05781M -3.97411M 0.30M 8.87M
Other cashflows from financing activities 0.00000M -0.89506M 17.51M 5.42M 5.42M
Change to netincome - 4.32M 10.12M 6.01M -0.39200M
Capital expenditures 7.12M 4.53M 1.38M 1.69M 1.56M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.17M 0.14M 0.13M 0.00400M 0.00400M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -7.12440M -4.52737M -1.37703M - -

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARX
Aroa Biosurgery Ltd		 0.01 2.94% 0.53 - 67.57 2.04 2.04 2.06 59.96
COH
Cochlear Ltd		 0.64 0.22% 296.13 51.08 41.84 8.07 9.86 7.92 30.61
PNV
Polynovo Ltd		 -0.035 2.90% 1.17 121.00 57.47 7.20 11.03 7.09 89.08
IMR
Imricor Medical Systems Inc		 0.005 0.33% 1.52 - - 511.02 3.97 336.99 -2.6027
EBR
Ebr Systems Inc CDR		 0.09 7.94% 1.16 - - - 17.93 -3.6785

Reports Covered

Stock Research & News

View All

Profile

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Aroa Biosurgery Ltd

64 Richard Pearse Drive, Auckland, New Zealand, 2022

Key Executives

Name Title Year Born
Dr. Brian Ward Founder, CEO, MD & Exec. Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Sec. NA
Dr. Barnaby C.H. May Ph.D. Chief Scientific Officer NA
Ms. Tracy Weimar BA, MBA Company Sec. NA
Dr. Brian Ward Founder, CEO, MD & Executive Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Secretary NA
Mr. Scott Sherriff B.A., M.B.A. Chief Operating Officer NA
Ms. Neetha Alex-Kumar General Counsel NA
Mr. Frazer Murray Director of Global Marketing & Strategy NA
Ms. Yasmin Winchester B.Sc. Vice President of Quality, Regulatory & Sustainability NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.